Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
March 27, 2023 16:05 ET
|
Interpace Biosciences, Inc.
●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
November 14, 2022 16:41 ET
|
Interpace Biosciences, Inc.
Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
October 20, 2022 16:28 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
September 01, 2022 17:18 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
August 31, 2022 17:30 ET
|
Interpace Biosciences, Inc.
Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 ...
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
August 15, 2022 16:05 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
May 16, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
May 11, 2022 08:30 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in...
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
March 31, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
February 22, 2022 09:00 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...